2.06

1.48% 0.03

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $2.06, with a volume of 1.10M. It is up +1.48% in the last 24 hours and down -31.33% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Previous Close:

$2.03

Open:

$2.03

24h Volume:

1.10M

Relative Volume:

0.82

Market Cap:

$375.00M

Revenue:

Net Income/Loss:

$-236.93M

P/E Ratio:

-1.42

EPS:

-1.4507

Net Cash Flow:

$-206.44M

1W Performance:

-5.50%

1M Performance:

-31.33%

6M Performance:

+11.96%

1Y Performance:

+214.02%

1-Day Range:

$1.98

$2.10

1-Week Range:

$1.98

$2.205

52-Week Range:

$0.611

$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(857) 760-0900

Address

260 ARSENAL PLACE, SUITE 1, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	2.06	375.00M	0	-236.93M	-206.44M	-1.4507
VRTX Vertex Pharmaceuticals Inc	441.70	112.35B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.71B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	52.29B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	44.48B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	35.51B	5.36B	287.73M	924.18M	2.5229

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Mar-07-25	Downgrade	Stifel	Buy → Hold
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Apr 15, 2026

In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News

Apr 15, 2026

Apr 12, 2026

Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey

Apr 12, 2026

Apr 11, 2026

If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan

Apr 11, 2026

Apr 10, 2026

Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN

Apr 10, 2026

Apr 09, 2026

Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn

Apr 09, 2026

Apr 07, 2026

Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn

Apr 07, 2026

H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail

Apr 07, 2026

Apr 06, 2026

Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN

Apr 06, 2026

Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union

Apr 06, 2026

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 06, 2026

Apr 05, 2026

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail

Apr 05, 2026

Apr 03, 2026

Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union

Apr 03, 2026

Apr 02, 2026

Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat

Apr 02, 2026

Apr 01, 2026

ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan

Apr 01, 2026

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph

Apr 01, 2026

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail

Apr 01, 2026